Your browser doesn't support javascript.
loading
Cross-suppression of EGFR ligands amphiregulin and epiregulin and de-repression of FGFR3 signalling contribute to cetuximab resistance in wild-type KRAS tumour cells.
Oliveras-Ferraros, C; Cufí, S; Queralt, B; Vazquez-Martin, A; Martin-Castillo, B; de Llorens, R; Bosch-Barrera, J; Brunet, J; Menendez, J A.
Affiliation
  • Oliveras-Ferraros C; Unit of Translational Research, Catalan Institute of Oncology, Girona, Spain.
Br J Cancer ; 106(8): 1406-14, 2012 Apr 10.
Article in En | MEDLINE | ID: mdl-22491422

Full text: 1 Collection: 01-internacional Health context: 6_ODS3_enfermedades_notrasmisibles Database: MEDLINE Main subject: Skin Neoplasms / Glycoproteins / Signal Transduction / Drug Resistance, Neoplasm / Epidermal Growth Factor / Receptor, Fibroblast Growth Factor, Type 3 / ErbB Receptors / Antibodies, Monoclonal Type of study: Prognostic_studies Limits: Humans Language: En Journal: Br J Cancer Year: 2012 Document type: Article

Full text: 1 Collection: 01-internacional Health context: 6_ODS3_enfermedades_notrasmisibles Database: MEDLINE Main subject: Skin Neoplasms / Glycoproteins / Signal Transduction / Drug Resistance, Neoplasm / Epidermal Growth Factor / Receptor, Fibroblast Growth Factor, Type 3 / ErbB Receptors / Antibodies, Monoclonal Type of study: Prognostic_studies Limits: Humans Language: En Journal: Br J Cancer Year: 2012 Document type: Article